SAN CARLOS, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that Chief Financial Officer, Timothy Morris, will present a Company  overview and pipeline update at the Jefferies 2017 London Healthcare Conference on Thursday, November 16, 2017 at 10:00 a.m. GMT in London, United Kingdom.

A live audio webcast of the presentation will be available by visiting the Investors section of Iovance Biotherapeutics' website at  http://ir.iovance.com/. A replay of the webcast will be archived on Iovance Biotherapeutics' website for 30 days following the presentation.

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The Company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck and recurrent and metastatic or persistent cervical cancer. For more information, please visit  http://www.iovance.com. 

Investor Relations Contact: Sarah McCabeStern Investor Relations, Inc.212-362-1200 sarah@sternir.com

Media Relations Contact:Evan Smith/Kotaro YoshidaFTI Consulting212-850-5622/212-850-5690 evan.smith@fticonsulting.com   kotaro.yoshida@fticonsulting.com